Altimmune appoints Richard Eisenstadt as CFO effective Dec 31, 2021

Altimmune, Inc.

William Brown resigns as CFO effective Dec 31, 2021 to pursue other opportunities; no disagreement.
Richard Eisenstadt appointed CFO effective Dec 31; annual salary $425,000, target bonus 40%, signing bonus $120,000.
Eisenstadt receives 150,000 stock options and 50,000 RSUs; options vest 25% at one year, balance over 36 months.
Eisenstadt previously CFO at Aytu BioPharma and Neos Therapeutics; raised over $340M in financings.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Brown

Chief Financial Officer

ALT · Altimmune, Inc.

Effective: 2021-12-31
Successor: Richard I. Eisenstadt
Filed: December 13, 2021, 6:59 PM ET

William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.

Appointed

Richard I. Eisenstadt

Chief Financial Officer

ALT · Altimmune, Inc.

Effective: 2021-12-31
Filed: December 13, 2021, 6:59 PM ET

the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Brown resigned as Chief Financial Officer at Altimmune, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

William Brown, the Chief Financial Officer, principal accounting officer and principal financial officer of Altimmune, Inc. (the “Company”), submitted notice to the Company’s Board of Directors (the “Board”) of his resignation, effective as of December 31, 2021.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard I. Eisenstadt was appointed as Chief Financial Officer at Altimmune, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the Company issued a press release announcing the decision of the Board to appoint Mr. Richard I. Eisenstadt as the Company’s Chief Financial Officer (“CFO”), effective December 31, 2021.

View on SEC.gov

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-148822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.